Management of castration-resistant prostate cancer: A call to urologists

BJU International

Volumn 110, Issue 6, 2012, Pages 772-774

  Fitzpatrick, John M ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; CABAZITAXEL; DOCETAXEL; MITOXANTRONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; TUBULIN;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANTINEOPLASTIC ACTIVITY; CANCER HORMONE THERAPY; CANCER SPECIFIC SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; CELL SURVIVAL; HUMAN; MALE; MICROTUBULE; NONHUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

ANDROGEN ANTAGONISTS; CASTRATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; UROLOGY;

EID: 84865472321     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11332.x     Document Type: Note

References (25)

1. Huggins C, Hodges CV,. Studies on prostate cancer. I. The effects of castration, of estrogen and androgen injection on serum phosphatises in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
2. Charles B,. Huggins-nobel lecture. Nobelprize.org. 2012. Available at: http://www.nobelprize.org/nobel-prizes/medicine/laureates/1966. Accessed 10 May 2012
3. Mottet N, Bellmunt J, Bolla M, et al,. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-83
4. Horwich A, Parker C,. Kataja V on behalf of the ESMO guidelines working group. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): 76-8
5. Eisenberger MA, Blumenstein BA, Crawford ED, et al,. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42
6. Montgomery RB, Mostaghel EA, Vessella R, et al,. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-54
7. Locke JA, Guns ES, Lubik AA, et al,. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration resistant prostate cancer. Cancer Res 2008; 68: 6407-15
8. Pienta KJ, Bradley D,. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1665-71
9. Tannock IF, Osoba D, Stockler MR, et al,. Chemotherapy with mitoxantrone plus prednisosn or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end-points. J Clin Oncol 1996; 14: 1756-64
10. Petrylak DP, Tangen CM, Hussein MHA, et al,. Docetaxel and estrasmustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
11. Tannock IF, de Wit R, Berry WR, et al,.; for TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
12. De Bono JS, Oudard S, Ozguroglu M, et al,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376: 1147-54
13. Sartor O, Oudard S, Ozguroglu M, et al,. Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. J Clin Oncol 2011; 29 (Suppl. 15): [abstract] 4525
14. Jordan MA, Wilson L,. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004 4: 253-65
15. Kuroda K, Liu H, Kim S, et al,. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009; 69: 1579-85
16. Gan L, Chen S, Wang Y, et al,. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009; 69: 8386-94
17. Zhu M-L, Horbinski CM, Garzotto M, et al,. Tubulin-targeting chemotherapy impairs receptor activity in prostate cancer. Cancer Res 2010; 70: 7992-8002
18. De Bono JS, Logothetis CJ, Molina A, et al,. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
19. Scher HI, Fizazi K, Saad F, et al,. Effect of MDV3100, an androgen receptor signaling inhibitor, on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol 2012; 30 (Suppl. 5): [abstract] LBA1
20. Scher HI, Beer TM, Higano CS, et al,. Antitumor activity of MDV3100 in castration-resistant prostate cancer. Lancet 2010; 375: 1437-46
21. Mezinski J, Attard G, Zivi A, et al,. Evaluating the antitumor activity of docetaxel following treatment with abiraterone acetate and steroids: evidence for cross-resistance. Crit Rev Oncol Hematol 2011; 78 (Suppl. 1): S23. (Abstract 31)
22. Tang Y, Khan MA, Goloubeva O, et al,. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 2006; 12: 169-74
23. Osborne CK, Kitten L, Arteaga CL, et al,. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by anti-estrogens. J Clin Oncol 1989; 7: 710-17
24. Albain KS, Barlow WE, Ravdin PM, et al,. Adjuvant chemotherapy and timing of tamoxifen in post-menopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomized controlled trial. Lancet 2009; 374: 2055-63
25. Attard G, Richards J, De Bono JS,. New strategies in metastatic prostate cancer: targeting the androgen receptor signalling pathway. Clin Cancer Res 2011; 17: 1649-57